Education
About Us
Working with TipRanks
Follow Us
BCAL Diagnostics Limited (AU:BDX)
ASX:BDX
RESEARCH TOOLSreports
BDX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.07 - AU$0.19
Previous CloseN/A
Volume98.04K
Average Volume (3M)128.73K
Market Cap
AU$30.01M
Enterprise ValueN/A
Total Cash (Recent Filing)AU$7.01M
Total Debt (Recent Filing)AU$1.30M
Price to Earnings (P/E)―
Beta-0.06
Next Earnings
Sep 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding365,967,900
10 Day Avg. Volume183,411
30 Day Avg. Volume128,728
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)2.97
Price to Sales (P/S)0.00
P/FCF Ratio-3.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
BCAL Diagnostics Limited News
PremiumCompany Announcements
BCAL Diagnostics Expands BREASTEST plus Access in Sydney and Melbourne
PremiumCompany Announcements
BCAL Diagnostics Launches Innovative Breast Cancer Blood Test
PremiumCompany Announcements
BCAL Diagnostics Launches Groundbreaking Breast Cancer TestPremiumCompany Announcements
BCAL Diagnostics Reports Increased Losses Amidst Strategic Expansion
PremiumCompany Announcements
BCAL Diagnostics Poised for BREASTEST® Launch and Market Expansion
PremiumCompany Announcements
BCAL Diagnostics Issues Shares to Boost Growth
PremiumCompany Announcements
BCAL Diagnostics Issues New Performance Rights---
Options Prices
Currently, No data available
---
Ownership Overview
20.94% Insiders
―
Mutual Funds
― Other Institutional Investors
79.06% Public Companies and
Individual Investors
BDX FAQ
What was BCAL Diagnostics Limited’s price range in the past 12 months?
BCAL Diagnostics Limited lowest share price was AU$0.07 and its highest was AU$0.18 in the past 12 months.
What is BCAL Diagnostics Limited’s market cap?
BCAL Diagnostics Limited’s market cap is AU$30.01M.
When is BCAL Diagnostics Limited’s upcoming earnings report date?
BCAL Diagnostics Limited’s upcoming earnings report date is Sep 02, 2025 which is in 106 days.
How were BCAL Diagnostics Limited’s earnings last quarter?
BCAL Diagnostics Limited released its earnings results on Feb 19, 2025. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.
Is BCAL Diagnostics Limited overvalued?
According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued.
Does BCAL Diagnostics Limited pay dividends?
BCAL Diagnostics Limited does not currently pay dividends.
What is BCAL Diagnostics Limited’s EPS estimate?
BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BCAL Diagnostics Limited have?
BCAL Diagnostics Limited has 365,967,900 shares outstanding.
What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?
BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.091%.
Which hedge fund is a major shareholder of BCAL Diagnostics Limited?
Currently, no hedge funds are holding shares in AU:BDX
---
BCAL Diagnostics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:BDX Sentiment 94%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.45%
12-Months-Change
Fundamentals
Return on Equity
-104.23%
Trailing 12-Months
Asset Growth
35.20%
Trailing 12-Months
Company Description
BCAL Diagnostics Limited
BCAL Diagnostics Limited (BDX) is a biotechnology company focused on developing innovative diagnostic solutions for the healthcare sector. The company's core product is a non-invasive blood test designed to detect breast cancer in its early stages, offering a promising alternative to traditional mammogram screening methods. BCAL Diagnostics aims to improve patient outcomes through early detection and intervention, leveraging advanced scientific research and technology.
---
Technical Analysis
---